BIRC5 and cancer: We hypothesized that the recombinant survivin-FLIPr fusion protein (rSur-FLIPr) is a broad-spectrum cancer vaccine candidate with the ability to target FcγRs, which is able to elicit survivin-specific immune responses against survivin-expressing cancers.